semaglutide launch FDA vs. HIMS: Why the Oral “Wegovy Copy” Crackdown Changes the GLP-1 Game Feds Launch Experiment to Have
Description
It did exactly what I needed it to do
A critical approach of guideline therapeutic recommendations for NAFLD
Semaglutide activates the GLP-1 receptor only
Acute kidney injury: Reported in patients treated with GLP-1 receptor agonists, often related to nausea, vomiting, and diarrhea leading to volume depletion
Beyond their primary indications in treating type 2 diabetes and high BMI, these medications have demonstrated potential benefits in addressing many of the conditions associated with NAION including hypertension, hyperlipidemia and obstructive sleep apnea, they wrote, likely as a result of their weight loss effects
